文献速递创面修复烧伤瘢痕与激光

纯化外泌体产品治疗皮肤移植供区:1b期临床试验

Clinical safety and regenerative potential of a purified exosome product in treating skin graft donor sites: A phase 1b trial.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2026-05-05

本研究为1b期前瞻性随机对照试验,纳入7例至少有两个等大刃厚皮片供区的受试者,一侧用标准护理、另一侧用纯化外泌体产品(PEP)。结果显示PEP单次应用(最高20%剂量)安全无相关不良事件,再上皮化时间与标准护理相当,无显著差异。

要点

  • PEP单次应用最高20%剂量在人体开放创面中安全性良好。
  • PEP组与标准护理组再上皮化时间无显著差异。
  • 需更大规模试验验证PEP在再上皮化中的疗效。

核心结论

  • PEP单次应用剂量高达20%在人体受试者中是安全的。
  • PEP与标准护理在供区再上皮化时间上无显著差异。

研究设计与样本

  • 1b期前瞻性、开放标签、对照、随机临床试验。
  • 纳入7例受试者,平均年龄49.3岁,每个受试者至少有两个等大的刃厚皮片供区。
  • 受试者分为低剂量PEP组和高剂量PEP组,每个受试者一侧供区用标准护理、另一侧用PEP。

主要发现

  • 未观察到与治疗相关的不良事件。
  • PEP组再上皮化中位时间18.5天(范围6-29天),标准护理组19.25天(范围8-314天),无显著差异。
  • 两组再上皮化时间相当。

关键数值与推荐

  • PEP单次应用剂量最高20%在人体中安全。
  • 安全性评估包括不良事件、实验室值、生命体征和体格检查。
  • 愈合评分采用温哥华瘢痕量表(VSS)和照片创面评估工具(PWAT)。

临床怎么用

  • PEP可作为开放创面安全应用的候选产品,但当前证据尚不支持其优于标准护理。
  • 临床决策应基于更大规模试验验证PEP在再上皮化中的疗效和统计学意义。

局限性

  • 样本量小(7例),需未来大型试验验证疗效。
  • 研究为开放标签设计,未设盲。
  • 标准护理组再上皮化时间范围宽(8-314天),数据变异大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this study was to determine the safety of the first clinically used purified exosome product (PEP) for open wounds. This was a phase 1b, prospective, open-label, controlled, randomized clinical trial of PEP in subjects with at least two equal sized split-thickness skin graft (STSG) donor site wounds with one donor site treated with standard of care (SOC) and the other treated with PEP. Patients were divided into low-dose PEP-only group and high-dose PEP-only group. Safety evaluations included occurrence of adverse events, laboratory values, vital signs, and physical examination findings. Wound healing was scored using Vancouver scar scale (VSS) and photographic wound assessment tool (PWAT). Seven subjects were included, with a mean age of 49.3 years. There were no adverse events related to the treatments. We observed comparable wound healing time between the treatments, with PEP-treated sites reaching 100% re-epithelialization at a median of 18.5 days (range, 6-29 days) and 19.25 days (range, 8-314 days) for SOC sites, without a significant difference. This study demonstrated that a single application of PEP at a dose as high as 20% was safe in human participants. Future large trials will be needed to validate PEP efficacy in re-epithelialization and determine its clinical and statistical significance.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Wan R, Wyles SP, Zhao C, et al. Clinical safety and regenerative potential of a purified exosome product in treating skin graft donor sites: A phase 1b trial. J Plast Reconstr Aesthet Surg. 2026. PMID: 42155421. doi:10.1016/j.bjps.2026.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。